Stock price at run: 196.55, Opinion: View analysis, Date: Tuesday, 2026-10-20 21:36 (EDT).
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to RVMD. [ FAQ on what and how to ask] For non-RVMD questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
No verified billionaire connection found.
Address: 700 Saginaw Drive, Redwood City, CA, United States, 94063
Employees: 883
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
CEO, President & Chairman
Chief Financial Officer
Chief Operating Officer
Senior VP, General Counsel & Corporate Secretary
Senior Advisor
Co-Founder & Chairman of Scientific Advisory Board
Academic Co-Founder & Member of Scientific Advisory Board
Academic Co-Founder & Member of Scientific Advisory Board
Chief Information Officer
Chief Scientific Officer
My Watchlist
